Man Group PLC Neurocrine Biosciences Inc Transaction History

Man Group PLC

$49.7 Billion
Q2 2025

A detailed history of Man Group PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Man Group PLC holds 47,226 shares of NBIX stock, worth $6.74 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

47,226

Previous 100,188 52.86%

Holding current value

$6.74 Million

Previous $11.1 Million 46.44%

% of portfolio

0.01%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$87.54 - $128.18 $4.64 Million - $6.79 Million	-52,962 Reduced 52.86%	47,226 $5.94 Million
Q1 2025 May 15, 2025	SELL	$107.22 - $153.29 $4.82 Million - $6.89 Million	-44,976 Reduced 30.98%	100,188 $11.1 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $16.9 Million - $21.1 Million	-151,015 Reduced 50.99%	145,164 $19.8 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $7.21 Million - $9.64 Million	62,954 Added 26.99%	296,179 $34.1 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $7.4 Million - $8.1 Million	-56,536 Reduced 19.51%	233,225 $32.1 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $3.74 Million - $4.12 Million	-28,673 Reduced 9.0%	289,761 $40 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $1.7 Million - $2.13 Million	-16,058 Reduced 4.8%	318,434 $42 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $27.9 Million - $34.7 Million	-296,255 Reduced 46.97%	334,492 $37.6 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $767,540 - $899,050	-8,573 Reduced 1.34%	630,747 $59.5 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $30.4 Million - $39.8 Million	323,350 Added 102.34%	639,320 $64.7 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $22.4 Million - $26.7 Million	210,283 Added 198.97%	315,970 $37.7 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $7.11 Million - $8.33 Million	77,245 Added 271.59%	105,687 $11.2 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $16.6 Million - $21.9 Million	-218,871 Reduced 88.5%	28,442 $2.77 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $996,187 - $1.3 Million	13,750 Added 5.89%	247,313 $23.2 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $18.6 Million - $24.8 Million	233,563 New	233,563 $19.9 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $184,509 - $251,575	-2,107 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $16.2 Million - $20.2 Million	-186,516 Reduced 98.88%	2,107 $202,000
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $9.02 Million - $12.7 Million	93,819 Added 98.96%	188,623 $18.1 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $4.01 Million - $6.15 Million	47,147 Added 98.93%	94,804 $11.6 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $2.63 Million - $3.98 Million	35,019 Added 277.09%	47,657 $4.12 Million
Q4 2019 Feb 18, 2020	BUY	$86.8 - $118.57 $442,593 - $604,588	5,099 Added 67.63%	12,638 $1.36 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $4.07 Million - $4.93 Million	-48,564 Reduced 86.56%	7,539 $679,000
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $2.17 Million - $2.74 Million	-30,075 Reduced 34.9%	56,103 $4.74 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $4.83 Million - $6.38 Million	-69,706 Reduced 44.72%	86,178 $7.59 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $9.65 Million - $17.6 Million	141,180 Added 960.15%	155,884 $11.1 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $259,065 - $329,727	-2,620 Reduced 15.12%	14,704 $1.81 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $385,912 - $543,198	-5,125 Reduced 22.83%	17,324 $1.7 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $1.7 Million - $2.07 Million	22,449 New	22,449 $1.86 Million

Others Institutions Holding NBIX

# of Institutions

663

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account